In addition to having a broad product portfolio that covers the full universe of foot recon/fixation procedures, Trilliant Surgical is the only provider of the novel Arsenal Foot Plating System™. With unique features designed for greater flexibility and speed of implant placement supporting ease of use, less waste and reduced OR time, Arsenal is poised to be a plating leader.

“Trilliant’s market-leading portfolio of foot and ankle solutions complements our acquisition of the STAR™ system and creates a dedicated foot and ankle business that significantly expands our mission of Powering Motion,” said Brady Shirley, CEO of DJO. “We are committed to building our Reconstructive segment and believe that the foot and ankle space is a great fit for our focused innovation and solutions approach that has allowed DJO to be a growth leader in the upper extremity market for many years.”

Among the factors driving the high-growth foot and ankle market are a rapidly growing elderly population, sports-related injuries, and the increasing prevalence of diabetes and related lower-extremity conditions. The Arsenal system addresses a number of mid- and hind-foot procedures and will be extended to ankle, with the potential to achieve significant additional penetration of medical procedures.

“As a foot and ankle champion since 2007, we are excited to join the DJO family and expand Trilliant Surgical’s positive patient impact globally,” said Jon Olson, CEO of Trilliant Surgical. “DJO’s unparalleled commitment to new product development, their iconic brands and strong growth trajectory will accelerate Trilliant’s ability to grow, innovate and improve patient outcomes.”

Total Ankle Replacement

DJO’s expansion into foot and ankle surgery complements its strong position in Total Ankle Replacements; in 2020, DJO acquired the Scandinavian Total Ankle Replacement (STAR) System, which holds a leading position in the global ankle arthroplasty market.

Ankle replacement surgeries have grown over the last decade, and according to Musculoskeletal Clinical Regulatory Advisors, as of February 2011 all public insurance programs, workers compensation and 92% of commercial insured patients have access to ankle replacement procedures when deemed medically necessary by a trained surgeon. ¹

For more information, visit djoglobal.com/TrilliantSurgical

Reference:

1. SmartTrak® Foot & Ankle Reimbursement: https://app.smarttrak.com/markets/qs/fd52946dc2bd8b02ac1002535b62cf35

England & Company served as exclusive financial advisor to the sellers.

About DJO®

DJO, a subsidiary of Colfax Corporation (NYSE: CFX), is a leading developer and distributor of high-quality medical devices that provide proven solutions for musculoskeletal health, joint reconstruction, vascular health, and pain management. The Company’s extensive range of products and integrated technologies address the orthopedic continuum of care from performance and mobility to surgical intervention and post-operative rehabilitation; enabling people around the world to regain or maintain their natural motion. For additional information about DJO, please visit www.DJOGlobal.com.

CAUTIONARY NOTE CONCERNING FORWARD LOOKING STATEMENTS

This press release may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning DJO’s plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on DJO’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause DJO’s results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including actions by governments, businesses and individuals in response to the situation, such as the scope and duration of the outbreak, the nature and effectiveness of government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions, the impact on creditworthiness and financial viability of customers, and other impacts on DJO’s business and ability to execute business continuity plans, and the other factors detailed in Colfax’s reports filed with the U.S. Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Colfax’s filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. DJO disclaims any duty to update the information herein.